Abstract:Photoresponsive ruthenium (Ru) complexes have been extensively studied in the photodynamic therapy (PDT) of cancer. The metal-to-ligand charge transfer (MLCT) absorption maximum of most Ru complexes is located in the short-wavelength visible region, which is well suited for superficial tumors but shows inefficient therapeutic effects for more deep-seated ones. Moreover, Ru complexes are primarily located in the mitochondria or nucleus, always resulting in high levels of dark toxicity and DNA mutation. Herein, we reported a new ruthenium complex (Ru-I) for red-light-triggered PDT. The activation wavelength of Ru-I is successfully extended to 660 nm. Importantly, the complex photosensitizer can be quickly taken up by cancer cells and selectively accumulated in the lysosome, an ideal localization for PDT purposes. Intratumoral injection of Ru-I into tumor-bearing mice achieved excellent therapeutic effects and thus holds great promise for applications in lysosome localization photodynamic therapy.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsami.0c22551?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsami.0c22551</a>.Experimental details including synthetic methods of Ru-I and characterization; ESI-HRMS spectrum of compound 3 (Figure S1); 1H NMR spectrum of compound 3 (Figure S2); ESI-HRMS spectrum of compound 4 (Figure S3); 1H NMR and 13C NMR spectra of compound 4 (Figure S4); purity of Ru-I measurement by HPLC (Figure S5); HOMO and LUMO orbitals for Ru-I (Figure S6); absorption and emission spectrum of Ru-I in different solvents (Figure S7); stability of Ru-I with different treatments (Figures S8 and S9); ROS generation analysis (Figures S10–S12); cell imaging experiments (Figures S13–S17); in vitro photocytotoxicity evaluation (Figures S18–S20); and animal experiments (Figures S21 and S22) (<a class="ext-link" href="/doi/suppl/10.1021/acsami.0c22551/suppl_file/am0c22551_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Uridine-Modified Ruthenium(II) Complex as Lysosomal LIMP-2 Targeting Photodynamic Therapy Photosensitizer for the Treatment of Triple-Negative Breast Cancer

Red-Light-Responsive Ru Complex Photosensitizer for Lysosome Localization Photodynamic Therapy

Identification of a luminescent platinum(II) complex with BODIPY derivative as novel photodynamic therapy agent for triple negative breast cancer cells

A lysosome-targeted ruthenium(II) polypyridyl complex as photodynamic anticancer agent

Lysosome Targeting Bis-terpyridine Ruthenium(II) Complexes: Photophysical Properties and in Vitro Photodynamic Therapy.

Rational design of a lysosome-targeting and near-infrared absorbing Ru( ii )–BODIPY conjugate for photodynamic therapy

Sonoinduced Tumor Therapy and Metastasis Inhibition by a Ruthenium Complex with Dual Action: Superoxide Anion Sensitization and Ligand Fracture

Two-Photon Photodegradation of E3 Ubiquitin Ligase Cereblon by a Ru(II) Complex: Inducing Ferroptosis in Cisplatin-Resistant Tumor Cells

Dual-Responsive and ROS-Augmented Nanoplatform for Chemo/Photodynamic/Chemodynamic Combination Therapy of Triple Negative Breast Cancer.

Breakthrough in Cancer Therapy: Lutetium Texaphyrin-Celecoxib Conjugate for Immune and Photodynamic Treatment

Lutetium Texaphyrin-Celecoxib Conjugate as a Potential Immuno-Photodynamic Therapy Agent

Localization of Cancer Cells for Subsequent Robust Photodynamic Therapy by Ros Responsive Polymeric Nanoparticles with Anti‐metastasis Complexes Nami‐A

Rare Earth Nanoprobes for Targeted Delineation of Triple Negative Breast Cancer and Enhancement of Radioimmunotherapy

Ultrasound-targeted photodynamic and gene dual therapy for effectively inhibiting triple negative breast cancer by cationic porphyrin lipid microbubbles loaded with HIF1α-siRNA.

Lysosome-targeted Cyclometalated Ir(III) Complexes as Photosensitizer/Photoredox Catalysis for Cancer Therapy

The ruthenium complex assists in nuclear targeting and selective killing of tumor cells

Substituent‐Modulated Excited Triplet States and Activities of Ruthenium Complexes for Dual Photodynamic/Sonodynamic Therapy to Cisplatin‐Resistant Non‐Small Cell Lung Cancer

A dual-targeting ruthenium nanodrug that inhibits primary tumor growth and lung metastasis via the PARP/ATM pathway

A Near-Infrared and Lysosome-Targeted Coumarin-Bodipy Photosensitizer for Photodynamic Therapy Against HepG2 Cells

Tumor oxygenation nanoliposomes promote deep photodynamic therapy for triple-negative breast cancer

Trifluoromethyl-pyrrolidone phthalocyanine nanoparticles for targeted lipid droplet imaging and in vitro photodynamic therapy in breast cancer cells